Zacks Research Has Bullish Estimate for CORT Q4 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research boosted their Q4 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Zacks Research analyst K. Das now anticipates that the biotechnology company will earn $0.54 per share for the quarter, up from their prior forecast of $0.53. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.73 EPS, Q4 2026 earnings at $0.73 EPS and FY2026 earnings at $2.47 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.14. The company had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. Corcept Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 EPS.

Other equities analysts have also recently issued reports about the stock. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Truist Financial upped their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics presently has an average rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Stock Performance

CORT opened at $58.91 on Thursday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market cap of $6.17 billion, a price-to-earnings ratio of 46.66 and a beta of 0.56. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $62.22. The business has a 50 day moving average of $54.85 and a 200-day moving average of $45.44.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.88, for a total transaction of $131,736.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider William Guyer sold 6,606 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $48.97, for a total transaction of $323,495.82. Following the completion of the transaction, the insider now directly owns 5,796 shares in the company, valued at approximately $283,830.12. This represents a 53.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,011 shares of company stock valued at $1,951,268. 20.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Corcept Therapeutics by 0.6% in the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock valued at $162,871,000 after purchasing an additional 19,893 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Corcept Therapeutics by 4.2% during the second quarter. Dimensional Fund Advisors LP now owns 2,676,335 shares of the biotechnology company’s stock worth $86,952,000 after acquiring an additional 108,658 shares in the last quarter. Geode Capital Management LLC boosted its position in Corcept Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company’s stock valued at $110,108,000 after buying an additional 99,470 shares in the last quarter. FMR LLC grew its stake in shares of Corcept Therapeutics by 24.6% during the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after buying an additional 269,074 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in shares of Corcept Therapeutics by 40.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock worth $56,637,000 after buying an additional 352,947 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.